ARQ 751

Drug Profile

ARQ 751

Alternative Names: ARQ751

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator ArQule; Daiichi Sankyo Company
  • Developer ArQule
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 09 Mar 2017 ArQule has patent protection for ARQ 751 in USA, European Union, Australia, China, Hong Kong, Israel, Japan, Mexico, Malaysia, Macau, New Zealand, Philippines, Singapore and South Africa (ArQule's form 10-K, filed in March 2017)
  • 01 Jun 2016 Phase-I clinical trials in Solid tumours in USA (PO) (NCT02761694)
  • 16 Apr 2016 Pharmacodynamics from a preclinical study in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top